Business Context and Reporting Period
This Form 8-K Current Report, dated June 21, 2024, covers events reported by Intellia Therapeutics, Inc. (NTLA) on June 26, 2024. The filing primarily addresses executive leadership changes within the finance department and the approval of a new equity incentive plan.
Key Financial Metrics
The filing does not contain operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and corporate governance matters.
Material Changes
Executive Leadership Transition
- Departure: Glenn Goddard, current Chief Financial Officer (CFO), will step down effective June 30, 2024. The departure is not related to any disagreement with the Company.
- Appointment: Edward Dulac is appointed as Executive Vice President and CFO, effective July 22, 2024.
- Interim Role: Michael P. Dube, Chief Accounting Officer, will serve as interim principal financial officer until Mr. Dulac's start date.
Compensation and Equity
- New CFO Compensation: Mr. Dulac's package includes a $510,000 annual base salary, a target cash bonus of 40% of base salary, and a $100,000 one-time sign-on bonus.
- Equity Grants: Mr. Dulac received an initial equity grant with a total grant date value of $4,200,000, consisting of stock options ($1.68M), time-based RSUs ($1.68M), and performance-based RSUs ($840,000 target value plus 30,000 shares).
- Separation Terms: Mr. Goddard is entitled to severance payments and benefits consistent with his employment agreement for a termination without Cause.
2024 Inducement Plan
- The Board approved the Intellia Therapeutics, Inc. 2024 Inducement Plan to facilitate the hiring of Mr. Dulac.
- The plan reserves 850,000 shares of common stock for issuance.
- Awards under this plan are restricted to new employees or rehired employees as an inducement material to entering employment.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, operational outlook, or discuss specific business risks. It notes that Mr. Dulac will be subject to an indemnification agreement covering expenses, judgments, and fines incurred in his service as an officer. The sign-on bonus is subject to repayment if Mr. Dulac terminates employment without Good Reason or is terminated for Cause prior to the second anniversary of his start date.
Investor Verification Checklist
- Verify the exact effective dates for the CFO transition (June 30, 2024, for departure; July 22, 2024, for appointment).
- Review the full text of the Employment Agreement (Exhibit 10.1) for detailed severance and performance metrics.
- Confirm the dilution impact of the 850,000 shares reserved under the 2024 Inducement Plan.
- Check subsequent filings for the execution of Mr. Goddard's separation agreement and release.